X Facebook LinkedIn WhatsApp Press Releases Any 2024 2023 2022 2021 2020 2019 2018 2017 (-) 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2016 December 27, 2016 argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine December 13, 2016 argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients November 30, 2016 argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting November 6, 2016 argenx to Present at Upcoming Investor Conferences October 25, 2016 argenx Reports Third Quarter 2016 Financial Results and Provides Business Update October 3, 2016 Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody™ September 21, 2016 argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York September 13, 2016 argenx to host inaugural R&D day and webcast on September 22, 2016 August 24, 2016 argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results August 3, 2016 argenx to Present at Wedbush PacGrow Healthcare Conference August 2, 2016 argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016 June 28, 2016 argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »